ENLV (Enlivex Therapeutics Ltd.) חוב לטווח קצר להון

Enlivex Therapeutics (ENLV) is based on Allocetra platform patents, creating a significant technological barrier, although R&D expenses are weighing on its market capitalization. The business relies on the development of sepsis therapy, where low demand elasticity guarantees high margins and stable FCF. This price chart illustrates the trend of the indicator, which currently stands at 0.00. However, local conflicts in the Middle East are complicating the transportation of biomaterials and laboratory operations.

The analysis of Enlivex Therapeutics (ENLV) resilience to market shocks relies on the support of funds that trust the Allocetra platform within the field of intensive care. GURU.Markets tools assess the share of liabilities maturing within one year relative to equity through the dynamics of short-term liabilities to own funds, allowing investors to identify critical debt peaks by comparing current values with the company's historical trend.